Best of Immunology and Biologics Educational Collaborative (IBEC) 2016: Focus on Advancements in Rheumatoid and Inflammatory Arthritis
Release Date: December 15, 2016
Expiration Date: December 15, 2017
Estimated Time to Complete Activity: 1.25 hours
This activity is supported by educational grants from:
Bristol-Myers Squibb, Lilly, and Pfizer
The intended audience for this activity is rheumatologists, rheumatology nurses, and other health care professionals involved in the treatment of patients with RA.
Leonard H. Calabrese, DO
Jonathan Kay, MD
William F.C. Rigby, MD
Joseph E. Craft, MD
John J. Cush, MD
Elizabeth Kirchner, CNP, MSN
Sergio Schwartzman, MD
Gregg Silverman, MD
Kevin D. Deane, MD, PhD
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
Valerie Zimmerman, PhD
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose. Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, authors, and reviewers involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 15, 2016 to December 15, 2017.
How to Participate in this Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives and articles, complete the CME posttest, and fill in and return the registration form and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™certificate within 4 to 6 weeks.
Rheumatoid arthritis (RA) is a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joint, leading to joint destruction, debility, and deformity. Increased understanding of the underlying pathophysiology of RA has made a remarkable difference in its treatment and prognosis. Numerous therapeutic agents with diverse targets and mechanisms have been added to the RA armamentarium, allowing for intervention at various stages in the pathogenic process of the disease. Mechanisms of autoimmunity and inflammation will be compared to the emerging role of checkpoint therapy and small molecules in novel treatment approaches. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as efficacy profiles of current and emerging therapies. This monograph will review checkpoint and small molecule therapy for RA, as well as early RA and use of biosimilars in clinical practice.
Upon successful completion of this educational activity, participants should be better able to:
- Explain the clinical and immunologic progression of RA from asymptomatic autoimmunity to pre-RA and RA and relate the role of anti-citrullinated protein antibodies (ACPAs) and gene interactions to this process.
- Assess the scientific basis for small molecule therapy of RA and allied condi- tions (kinase inhibitors, PPD inhibitors, and others) as well as compare and contrast data on efficacy and toxicity from these agents versus other immune- based therapies.
- Detail the challenges in interpreting safety data from studies of biologic and immune-based therapies derived from randomized trials, extension studies, and registries.
- Examine the bioengineering and regulatory basis of biosimilar drug develop- ment and critically appraise both the advantages and risks of their potential use in practice.
Contact us at CME@VindicoCME.com
Contact Information for Technical Questions
Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email email@example.com.
This continuing medical education (CME) supplement is originally developed content for the purpose of this activity only. Neither the editors of Rheumatology News nor the Editorial Advisory Board nor the reporting staff contributed to its content. The opinions expressed are those of the faculty and do not necessarily reflect the views of the supporter or the Publisher.
Published by Global Academy for Medical Education, LLC and Frontline Medical Communications, LLC at Rockville, MD. Content created by Vindico Medical Education at 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Printed in the USA. Copyright © 2016 Global Academy for Medical Education, LLC, and Frontline Medical Communications, LLC at Rockville, MD and Vindico Medical Education.
All rights reserved.
No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the publisher. The opinions or views expressed in this supplement are those of the faculty and do not necessarily reflect the opinions or recommendations of the provider, the supporter, or of the publishers. Neither Global Academy for Medical Education, Frontline Medical Communications, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product. The Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.